Durect (DRRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

DRRX Durect

Watchlist

0.9500
+0.0920+10.72%

Close Dec 20 16:00 ET

0.9500
0.00000.00%

Post 20:01 ET

29.49MMarket Cap-1.48P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Oppenheimer Remains a Buy on Durect (DRRX)
TipRanksNov 26 07:46 ET · Ratings
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
ReutersNov 25 11:34 ET
DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
BenzingaNov 25 06:05 ET
Express News | DURECT Corp - Transaction Extends DURECT Cash Runway Through First Half of 2025
ReutersNov 25 06:00 ET
Express News | DURECT Corporation Announces Sale of Alzet® Product Line to Lafayette Instrument Co. for $17.5 Million
ReutersNov 25 06:00 ET
Branford Castle-Backed Lafayette Instrument Acquires Alzet Osmotic Pumps
PR NewswireNov 25 06:00 ET

Comments

MARKET-TEST-DUMMY

Dec 6 20:15

👁

$Durect (DRRX.US)$

Jaguar8

Nov 25 05:07

NEWS

$Durect (DRRX.US)$
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
DURECT (DRRX) has sold its ALZET® osmotic pumps product line to Lafayette Instrument Co. for $17.5 million. The transaction includes certain assets and liabilities associated with the ALZET line.
DURECT used the proceeds to pay off its remaining obligations under the Oxford Finance term loan.
The company states this sale strengthens its cash position and extends runway t...

Form 4

NEWS

$Durect (DRRX.US)$
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint;topline results expected within two years of trial initiation
- Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b tr...